Mural Oncology (MURA)
NASDAQ: MURA
· Real-Time Price · USD
2.07
0.00 (0.00%)
At close: Sep 08, 2025, 3:59 PM
2.07
0.00%
After-hours: Sep 08, 2025, 05:09 PM EDT
Company Description
Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer.
The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.
It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs.
The company was incorporated in 2017 and is based in Dublin, Ireland.
As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.
Mural Oncology
| Country | IE |
| IPO Date | Nov 16, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 116 |
| CEO | Caroline J. Loew |
Contact Details
Address: 10 Earlsfort Terrace Dublin, IE | |
| Website | https://www.muraloncology.com |
Stock Details
| Ticker Symbol | MURA |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001971543 |
| CUSIP Number | n/a |
| ISIN Number | IE000LK2BOB4 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Caroline J. Loew Ph.D. | President, Chief Executive Officer & Director |
| Adam D. Cutler B.A. | Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer |
| Maiken Keson-Brookes | Chief Legal Officer |
| Dr. Vicki L. Goodman M.D. | Chief Medical Officer |
| Justin Levine | Head of Human Resources & Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 02, 2025 | SCHEDULE 13G | Filing |
| Sep 02, 2025 | 3 | Filing |
| Aug 20, 2025 | DEFA14A | Filing |
| Aug 20, 2025 | 8-K | Current Report |
| Aug 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Aug 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Aug 05, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Aug 04, 2025 | 10-Q | Quarterly Report |
| Aug 04, 2025 | 8-K | Current Report |
| Jul 23, 2025 | 4 | Filing |